Insignis Therapeutics and HLK Pharmacin Receive FDA IND Clearance to Initiate a Phase 1 Trial With IN-001 for Oral Anaphylaxis Treatment
October 29, 2020 07:30 ET
|
Insignis Therapeutics, Inc.
Trial to initiate this quarter with data anticipated in 2021 Convenient oral alternative to injectable epinephrine NORTH HAVEN, Conn. and NEW HAVEN, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) --...